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Key messages 
 
• Medication adherence is often suboptimal after stroke. 
• Interventions to improve medication adherence have limited effectiveness. 
• The burden of ‘medicines work’ is substantial and multifaceted.  
• It relies on trust between stroke survivors, carers and health professionals. 
• Trust in the benefits of medicines themselves is also important. 
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Abstract  
Background  
Lifelong secondary prevention medication is recommended after stroke or transient ischaemic 
attack. However, poor medication adherence and persistence, which lead to suboptimal health 
outcomes, are common, but the reasons for this are not well understood, mainly because there have 
been few studies reporting adherence barriers in stroke survivors.  
 
Objective 
The aim of this review was to undertake a meta-synthesis of qualitative studies of medication-taking 
after stroke. Outcomes of interest were: lived experiences, views and beliefs, and strategies and 
solutions used by community-dwelling stroke and TIA survivors, informal carers and healthcare 
professionals in relation to medication taking. 
 
Method 
The review protocol was registered on PROSPERO (CRD42018086792). A search of online 
bibliographic databases was performed using key search terms of stroke, persistence, adherence and 
medication for years 1980-2018.  Citation tracking was also carried out. Studies using qualitative or 
mixed methods were included.  Systematic data extraction and synthesis were conducted using a 
meta-ethnographic approach. 
 
Results 
Twelve studies were eligible for inclusion, with a total of 412 participants, two-thirds of whom were 
stroke survivors, ranging from 1 month to over 20 years post-stroke. Third-order themes identified 
were ‘Medicines Work’ – Information Work; Health Care Work; Carer Work; Emotional Work; 
Practical Work; and an underpinning theme of Trust. However, many studies had significant 
methodological weaknesses. 
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Conclusions  
This synthesis suggests that the burden of ‘medicines work’ after stroke is substantial and 
multifaceted. Its successful undertaking depends on mutual trust between stroke survivors, carers 
and health care professionals, and trust in the benefits of medicines themselves. 
 
Key words 
Medication Adherence; Patient Experience; Qualitative Research; Secondary Prevention; Stroke; 
Systematic Review. 
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Background  
 
Survivors of stroke or transient ischaemic attack (TIA) need several long-term medications for 
optimum secondary prevention1 of recurrent stroke or other vascular disease (coronary artery and 
peripheral vascular disease), in addition to medication for any comorbidities. Adherence to 
secondary prevention medication reduces the risk of stroke recurrence by around 80%2. Poor post-
stroke medication adherence (MA) is, however, a common and clinically important problem3. Two-
thirds of stroke survivors need medication advice at 6-9 months4, less than half feel sufficiently 
informed about stroke prevention5, and many have other unmet needs in relation to medication 
management6.  There is limited evidence for the effectiveness of interventions to improve secondary 
stroke prevention7, and although a number of national clinical guidelines for stroke include 
recommendations to support MA, these are mainly based on consensus1,8,9 . 
 
A better understanding of the barriers and enablers of MA could lead to the design of effective and 
feasible interventions which would have far-reaching effects on health10. Interventions which are not 
grounded in this way are likely to have limited effectiveness11. Research priorities for MA support 
(for any condition) include the evaluation of intervention strategies targeted to specific problems 
and subgroups12. However, people’s experiences of the barriers and enablers of MA after stroke 
might be very different from those affecting the general population or those with other clinical 
conditions, because of such factors as the presence of residual physical or cognitive neurological 
disabilities. It may also be important to consider the presence of common comorbidities such as 
diabetes mellitus or coronary heart disease, and the additional medication needs imposed by these 
conditions. It is thus important to understand the perceptions and experiences of stroke survivors, 
informal carers, and health care professionals (HCPs) in relation to the barriers and enablers which 
may affect post-stroke MA, in order to provide appropriate support and to develop evidence-based 
interventions for future evaluation. Reviews have previously been undertaken of studies evaluating 
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the effectiveness of interventions to support MA after stroke7, and of quantitative studies of 
predictors of MA after stroke13. Other reviews have synthesised the qualitative literature on related, 
non-stroke-specific topics such as people’s beliefs and attitudes to taking statins14, patients’ and 
carers’ knowledge, attitudes and beliefs about medication adherence15, medication-related 
burden16, and medication taking in coronary artery disease17. However, there are no published 
syntheses of the qualitative literature exploring the views and experiences of stroke survivors, carers 
and HCPs on this topic.  
 
The objective of this review was to undertake a qualitative meta-synthesis of the evidence base 
exploring the views and lived experiences of community-dwelling stroke and TIA survivors, informal 
carers and healthcare professionals in relation to medication taking after stroke. 
 
Methods 
Search strategy 
An initial unpublished search of the literature, yielding 4 studies, was undertaken in 2013 and 
repeated for this review. The search strategy was developed from a scoping review and from the 
Cochrane Stroke Review Group short form search for stroke. Specific terms relating to secondary 
prevention, adherence, persistence, and medication were used to search relevant bibliographic 
databases (Medline, Biomed Central, CINAHL, AMED, EMBASE, psycINFO, British Nursing Index, Web 
of Science, NLM Gateway, PharmWeb and Bibliomap) for literature published from 1st January 1980 
to 18th January 2018. (See Supplementary file 1 for the full search strategy for Medline.) Forward 
and backward citation tracking was undertaken, including published systematic reviews relating to 
general medication taking, and reference lists of included articles.  Key policy documents, websites 
and grey literature were also searched.   
Inclusion and exclusion criteria 
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Development of the inclusion and exclusion criteria were informed by the initial scoping review, 
which suggested that available studies used a range of qualitative methodology, and often included 
the views and experiences of carers and HCPs as well as stroke survivors themselves. Articles were 
eligible for inclusion if they met the following criteria: 
Population: Community dwelling stroke or TIA survivors, their informal carers (e.g. family members), 
and any primary or secondary care HCPs who prescribe, advise or otherwise support people in 
medication taking after TIA or stroke.  
Exposure: Being prescribed, or being involved in the prescription, supply, or support in relation to, 
medication after TIA or stroke, for secondary prevention or any other co-morbidity. 
Outcomes of interest: 1) Lived experiences of community-dwelling stroke and TIA survivors, informal 
carers and healthcare professionals in relation to medication taking after stroke. 2) Views and beliefs 
of community-dwelling stroke and TIA survivors, informal carers and healthcare professionals to 
barriers and facilitators of medication taking.  3) Strategies and solutions used by community-
dwelling stroke and TIA survivors, informal carers and healthcare professionals to promote 
medication taking. 
Eligible study designs included: qualitative studies; mixed method studies that reported some 
qualitative data relating to the outcomes of interest; studies including heterogeneous samples of 
people after stroke/TIA and those with non-stroke conditions if at least some stroke/TIA-specific 
primary and/or secondary data was reported. 
Articles were ineligible for inclusion if they were: published only in abstract form; studies with no 
qualitative component; data related only to in-hospital or institutional medication taking; non-
stroke/TIA population; not published in the English language, due to lack of resources for translation. 
Data screening and selection of studies 
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Titles and abstracts were reviewed independently by pairs of reviewers against the 
inclusion/exclusion criteria. Full texts of potentially eligible studies were then retrieved and 
independently assessed by pairs of reviewers to identify the final studies for inclusion. Manual 
searching of the reference lists and citation tracking of included papers was conducted to identify 
any further potentially relevant studies. All qualitative studies that met the inclusion criteria were 
included regardless of epistemological underpinnings, as is common in the synthesis of health 
research18. Disagreements between reviewers were resolved through team discussions.  
Data Extraction 
Data were independently extracted by pairs of researchers using a bespoke data extraction form to 
ensure consistency. The form was initially tested on 3 studies and modified as necessary. Only data 
from the qualitative component of any mixed methods study, and only stroke-specific data from 
studies with heterogeneous stroke/non-stroke data, were included. Key information extracted from 
each of the primary studies included: bibliographic information; details of setting and location; 
population; research questions or aims, development of the interview schedule or other tools, data 
collection methods, data analysis methods, theoretical framework, and primary or secondary data 
relating to the outcomes of interest.  
Data Synthesis  
The meta-synthesis technique described by Noblit and Hare19 was used to synthesise the qualitative 
data, enabling collation and comparison of the evidence across the studies whilst preserving the 
meaning as interpreted by the original authors. First order constructs, as presented by the authors of 
the primary studies in the form of direct quotes from study participants were extracted and 
tabulated by authors 1-4. Second order constructs comprised interpretations, themes or statements 
developed by the primary studies’ authors in response to the first order constructs. Common and 
contradictory themes were explored across the studies. Using an inductive approach, the review 
team then developed third order constructs after combining and exploring first and second order 
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constructs to elicit an explanatory framework for the reported findings. At each stage of data 
synthesis, the team discussed and reached consensus on their interpretations.  
The quality of the included studies was appraised using Walsh and Downe’s criteria20. Pairs of 
researchers independently assessed each included study and then discussed their ratings to reach 
consensus. In addition to the published domains for data appraisal, we added an appraisal of the 
reporting of patient, carer and public involvement (PCPI) in the studies’ design and conduct, because 
we felt that its increasing recognition as an essential component of high quality and ethically sound 
health care research warranted its inclusion. As is common practice in qualitative meta-synthesis, 
studies were included irrespective of their overall quality.  
The research team included health services researchers with expertise in clinical nursing (authors 1 
and 3) as well as expertise in systematic review (authors 2, 3, and 4). The first author also holds a 
prescribing qualification and has led (with author 3) a qualitative study exploring stroke unit nurses’, 
stroke survivors’ and carers’ views and experiences of managing medication early after discharge. 
This study was registered on PROSPERO (CRD42018086792) at 
https://www.crd.york.ac.uk/PROSPERO. The reporting of this qualitative evidence synthesis is in 
accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA)21 (see Supplementary file) and the ENTREQ reporting guidelines for qualitative synthesis22.  
 
Results 
 
Our search strategy initially yielded 971 articles. Following exclusion of duplicates, and screening of 
the title, abstract or complete article, 12 studies met the inclusion criteria. The PRISMA flowchart 
(Figure 1) illustrates the flow of studies through the synthesis. Table 1 summarises the included 
studies.  
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Study participants, design, and quality  
The twelve eligible studies included a total of 412 participants, of whom 271 (66%) were stroke (246) 
or TIA (25) survivors, 106 (26%) were carers and 33 (8%) were HCPs or others; two were unknown. 
The time points of data collection were reported heterogeneously and ranged from 1 month to more 
than 20 years post-stroke.  
 
There were nine qualitative studies23,24,25,26,27,28,29,30,31 and three studies utilising mixed 
methods32,33,34. Nine studies utilised purposive sampling23,25,26,27,28,29,30,32,34, and three utilised 
convenience sampling24,29,33; some aspects of sampling were poorly justified.  Methods included 
semi-structured interviews24,25,26,27,29,31,32,33 ; semi-structured interviews and focus groups23,34, and 
analysis of on-line ‘chat room’ discussions28,30.  
 
Nine studies were assessed as being of moderate quality and three studies were assessed as being of 
weak quality. Common limitations in the studies included lack of an appropriate theoretical 
framework, absent key participant data (e.g. age, time since stroke), lack of data saturation, absent 
participant validation, ethical concerns, and failure to report or consider divergent views. Indeed, 
one study24 excluded the views of one interviewee (the only male participant) because his views 
were divergent. In most studies the professional background of the researchers was not explicitly 
reported, and the identity of the member or members of the research team who conducted the data 
collection was unclear, which limited considerations of reflexivity in this synthesis. Only two studies 
reported any PCPI activities, namely a formal PCPI group23 and the incorporation of stroke survivor 
feedback about the interview schedule27. 
 
Location of Studies and Types of Participants 
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Each study was conducted in a single country, including the UK23,26,27,28,29,30,31,32,33, USA24, France25 and 
Ghana34, the latter being the only low or middle income country (LMIC) represented. Participants 
included stroke survivors only29,31,32,33; stroke survivors and carers23,26,28,30; stroke survivors, carers 
and healthcare professionals25,27; stroke survivors, carers, community leaders and healthcare 
providers34, and carers only24. Where demographic information for stroke survivors was 
reported23,25,27,28,29,30,31,32,33 the mean age was 63.1 years (range 17-93); with 45% being female. Only 
one study25 reported carers’ ages (mean 60 years, range 40-78).  Four studies reported participants’ 
ethnicities24,29,31,33, of which only one24 reported the inclusion of participants of non-white 
ethnicities.  
 
Themes identified 
Two overall third order themes: Doing Medicines Work, and Trust, were developed from the first- 
and second-order themes reported. Doing Medicines Work encompassed several types of work; 
Information work; Healthcare work; Carer work; Emotional work and Practical work, all of which 
were  underpinned by Trust in HCPs, others, or in the medicines themselves. These themes are 
represented schematically in Figure 2. 
A synopsis of each theme is provided below, and exemplar first-order quotes for each theme and 
sub-theme are given in Table 2.  
 
1. Information work.  This subtheme includes all the work that stroke survivors do to obtain, 
understand and evaluate information about their medicines, such as the reason for the drug or 
drugs, the underpinning pharmacological and evidence base, and knowledge about how to take it. 
Positive examples of information work included HCPs taking time to explain the medication, the 
provision of written information by HCPs and their responsiveness to questions. However, many 
stroke survivors and carers reported a lack of information provision and of discourse around 
medications. Preferences for written or verbal information varied. There was also a need for ongoing 
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information, especially when medication brands were changed. Stroke survivors relied on visual cues 
about their medication, such as its colour, shape or packaging, but HCPs did not volunteer 
information about this which led to confusion and further information seeking by the stroke 
survivor.  
 
2. Healthcare work. This subtheme includes the work that stroke survivors undertake to engage with 
health care services in order to obtain their medicines, arrange and attend monitoring and 
medicines review. It also includes the reciprocal work performed by HCPs and the interactions 
between stroke survivors and HCPs. Negative aspects of healthcare work included dislike of the need 
for monitoring such as blood tests for vitamin K antagonists (warfarin), and the ‘kerfuffle’ of 
arranging medical review appointments, which were seen as a scarce resource. This could lead to a 
total lack of ongoing medication support, as with the stroke survivor who had not seen their GP in 
the 14 months since their stroke. Even when ongoing healthcare advice was obtained it might have 
perceived negative consequences such as an additional medication being prescribed. However, 
there were some examples of stroke survivor-centred healthcare work where HCPs were responsive 
to stroke survivors’ and carers’ concerns and difficulties with medication.  
 
3. Carer work. This subtheme includes the work that informal carers (family members, friends or 
neighbours) perform to assist the stroke survivor with any other type of medicines work. The 
importance of carer work was referred to by stroke survivors and HCPs as well as carers themselves. 
Many examples entailed organising the medication, whereby carers took responsibility for obtaining 
medication supplies and establishing a system for the stroke survivor to be able to independently 
take their medication, but this could lead to errors if the carer was then not available. Carer work 
could also include overseeing medication-taking where direct supervision was felt to be needed, and 
facilitating access to HCP support. Interactions between stroke survivors and carers about the 
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medication also fell under this theme, and often included conflicts between the stroke survivor and 
carer. 
 
4. Emotional work. This subtheme includes the motivational work that stroke survivors and carers 
perform in relation to long-term medication taking. The perceived necessity for taking medication 
was framed in terms of fear of having another stroke, which was felt to have serious or potentially 
even fatal consequences. HCPs also recognised that MA was contingent on the stroke survivor 
understanding the risk of stroke recurrence. Some stroke survivors were unconcerned about missing 
medications occasionally. They also expressed concerns about taking medication, including a dislike 
of taking medication, particularly multiple medications, not being ‘back to normal’, stigma and 
embarrassment, and worries about potential physical harm such as side effects. Very few HCPs 
mentioned this emotional work that stroke survivors performed; one HCP even took a protective 
stance by suggesting that HCPs tended to avoid talking about the necessity for medication with 
stroke survivors as they were ‘already anxious’.  
 
5.Practical work. This subtheme includes a range of direct and indirect activity which is necessary for 
the stroke survivor to take their medication. It included logistical and technical work, including 
organising, storing, and keeping track of doses taken as well as the act of self-administering the 
medication. It also included dealing with difficulties caused by physical or cognitive sequelae of 
stroke that affected medication-taking. Successful medication adherence entailed work to evolve 
and maintain a routine. This often relied on interaction with other people, notably carers, and 
strategies and solutions to maintain routines when a change of circumstances threatened to derail 
medicines taking.  Enablers of practical work included the stability of the medication regime and of 
the stroke survivor’s daily routine; barriers included the need to modify the routine and the 
complexity of the regime. Affordability of medication for stroke survivors was a concern in two non-
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UK studies, although one UK study also discussed the impact of cost-saving measures within the 
National Health Service on the availability of specific brands of medication. 
 
6. Trust. This theme encapsulates the trust that stroke survivors and carers have to develop in the 
efficacy of the medication in terms of its potential benefits. Trust could be hampered by the 
imperceptible benefit conferred by medications for stroke prevention, whereby efficacy could 
ultimately be evaluated only by the continued non-recurrence of stroke. The concomitant reduction 
in risk of coronary artery or peripheral vascular disease was not noted by any participants. However, 
some participants expressed different degrees of trust in the efficacy of specific medication. Where 
they readily understood the mechanism of action, or they had evidence from a surrogate endpoint 
such as blood pressure reduction, this contributed to their trust in the efficacy of that medication.  
Medicine-taking was also mediated by beliefs about healthcare, including trust, or lack of it, in 
individual practitioners and in the healthcare system as a whole. Notably in the one study conducted 
in a LMIC, there was a lack of trust in modern medicines.  
 
Conclusions 
 
This qualitative synthesis has identified the various types of medicines work reported in the 
literature that are performed by stroke survivors, carers and HCPs in order to establish and maintain 
a medication regime after stroke. This complex medicines work and the underpinning need to 
develop trust are likely to constitute a substantial treatment burden, regardless of the severity of the 
stroke.  
 
There are some areas of this body of literature where high quality evidence is particularly scarce. 
These include the views of carers, even though 7 of the 12 included studies recruited at least some 
carers, which is noteworthy given the increasing recognition of the value of carer support in many 
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aspects of life after stroke and in MA generally. Data about the impact of the physical and cognitive 
sequelae of stroke on people’s medication adherence are also scant.  It is unclear whether this 
represents absence of problems in the population studied, given that they may have been younger 
and less disabled by their stroke than the general stroke population, or is due to the studies’ designs 
and content.  
 
Our comprehensive search strategy enables us to suggest with confidence that we have included 
most studies published in English up to January 2018. As with any review, publication bias may have 
influenced the results37. We limited the search to studies published in English, and 10 of the 12 
studies were from Anglophone countries, with only one being conducted in a LMIC, and with each 
included study being conducted in a single country. Some of the issues identified (e.g. access to and 
cost of medications) may be highly context-dependent due to international variations in the 
organisation and funding of health care, especially given the preponderance of studies from the UK 
and the scarcity of studies from LMICs.  
 
Given the complexity of ‘medicines work’ and the inherent resistance to taking medicines after 
stroke that is highlighted by this review, it is perhaps not surprising that it has thus far proved 
difficult to design interventions that are effective in improving MA and clinical outcomes7. Such 
interventions would need to take account of diverse and unique sets of predictors of and barriers to 
MA which affect different stroke survivors in order to be effective. Although some of these barriers 
have been identified in observational studies13, it is not clear who is most at risk of poor MA, nor 
what types of interventions are most suited to which individuals. This individualisation of medicines 
support is not easily captured in a study protocol, practice guideline or manual. Furthermore, the 
importance of trust as a keystone to MA after stroke underpins the role of the individual stroke 
survivor/health professional partnership in the provision of tailored support. While it may be a 
relatively simple task to identify, and formulate a plan to overcome, some barriers to MA after 
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stroke (for example, problems with manual dexterity), it is perhaps more difficult to identify and 
address the complex issues of trust which underlie much intentional non-adherence, particularly as 
stroke survivors may not wish to jeopardise their working relationship with HCPs by expressing lack 
of trust in their treatment. The importance of this partnership may also underlie some of the 
problems with the implementation of potentially useful interventions into everyday practice, 
because the stroke survivors who have participated in clinical trials and the development of 
interventions are not necessarily representative of the wider populations of interest in terms of their 
beliefs about, and trust in, health care interventions.  
 
Our categories of ‘medicines work’ align to some extent with previously described elements of 
treatment burden in stroke26.  The need for trust in MA after stroke also aligns with the concepts of 
necessity and concerns which underpin much thinking around medication adherence35. Trust in 
medicines will be present when the individual’s perception of their necessity outweighs any 
concerns they may have. It may be highly context-dependent, as illustrated by the presence of trust 
in traditional healers and lack of trust in ‘western’ medicine described in one included study34. The 
lack of trust in medicines after stroke also concurs with findings from a synthesis of medicine-taking 
across all health conditions that people are reluctant to take medicines and generally prefer to take 
as few as possible36. Some of the findings of other recent relevant reviews also resonate with the 
themes presented here. In studies of people’s beliefs and attitudes to taking statins14, trust in the 
efficacy of the medication and in HCPs were important, and in studies of medication taking in 
coronary artery disease17, working relationships with prescribing clinicians were critical. Across all 
health care conditions, a general review of patients’ and carers’ knowledge, attitudes and beliefs 
about medication adherence15 found that beliefs about medications, family support, and the role of 
HCPs were important, and a review of medication-related burden16 suggested that patients’ lived 
experiences of medicines and associated treatment burden needed to be appreciated by HCPs.  
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This review of specific barriers, facilitators and predictors of medication persistence and adherence 
post-stroke has identified many gaps and quality issues in the literature. Of particular note, there are 
few studies which covered the period early after stroke when people are adjusting to their diagnosis 
and their new or altered medication regime. The available literature focuses almost entirely on the 
experiences of stroke survivors in countries in the global North, with only one study conducted in a 
LMIC and only one further study reporting the inclusion of any non-caucasian participants. Although 
carers and HCPs constituted 26% and 8% respectively of the participants across all 12 studies, the 
experiences of carers, in particular, were only reported superficially. The sole study which focused 
only on carers was assessed as poor quality. Further high-quality studies on this topic should 
endeavour to address these gaps in the literature. 
 
Many of the issues discussed here are not necessarily specific to stroke, and might also apply to 
people taking long-term medication for many conditions. Whilst it is important to address condition-
specific issues it may also be fruitful to carefully consider the relevance of the findings of similar 
studies in other conditions and populations, such as cardiovascular primary prevention, secondary 
prevention in coronary artery disease and peripheral vascular disease, multimorbidity, and 
polypharmacy, when designing future research studies and interventions. As a corollary, researchers 
and practitioners in these other fields may wish to address some of the issues identified in this 
review. 
 
This synthesis illustrates strongly that the burden of medicines work after stroke is substantial and 
multifaceted, and depends on mutual trust between stroke survivors, carers and HCPs, as well as 
trust in the benefits of medicines themselves. To better support stroke survivors, HCPs working with 
stroke survivors need to consider ways in which they can support clear information exchange, 
minimise the work for patients in accessing medication support from the health care system, help 
carers to be engaged in supporting the stroke survivor, address people’s beliefs and concerns about 
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their medication and the risk of recurrent stroke, and develop individualised strategies to address 
practical problems experienced by stroke survivors in relation to taking medication.   
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Figure 1: Flow chart illustrating the literature search for qualitative meta-synthesis of medication-
taking after stroke. 
Figure 2. Themes identified in qualitative meta-synthesis of studies of medication-taking after 
stroke. 
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Table 1: Summary of studies in qualitative synthesis of medication-taking after stroke, 1980-2018. 
First Author, 
Year and 
Country  
Participants Time 
point 
Sampling Data 
Collection 
Methods 
 Mean Age 
(range) 
 Female 
(%) 
Topic 
Allison, 2008, 
UK 
38 (25 stroke 
survivors and 13 care 
givers) 
3 to 24 
months 
post 
stroke 
Purposive 25 face-to-
face 
interviews 
and 4 focus 
groups 
69.5 (37-91) 
stroke 
survivors 
44% 
stroke 
survivors; 
62% care 
givers 
Knowledge of risk of hypertension; experiences of 
receiving information; feedback on the educational 
resource provided; testing utility of the resource 
Bakas, 2002, 
USA 
14 stroke family care 
givers 
Within 6 
months 
post 
discharge 
Convenience 13 telephone 
interviews; 1 
face-to-face 
interview  
NS 100% 
care 
givers 
5 questions: 1. What is a typical day providing care for a 
stroke survivor? 2. Do you have any concerns or 
problems since the stroke survivor has returned home? 
3. What have you found helpful in terms of dealing with 
concerns or problems? 4. What advice would you give 
someone else in the same situation? 5. If we were to 
develop a programme to help care givers what would be 
most helpful? 
Bauler, 2012, 
France 
26 (8 stroke 
survivors, 6 care 
givers, 4 physicians, 8 
nurses) in outpatient 
and inpatient rehab 
units 
1 month 
to more 
than 10 
years 
Purposive Face-to-face 
interviews 
53.4 (38 to 67) 
stroke 
survivors; 60 
(40 to 78) care 
givers; 28 (23 
to 35) health 
professionals 
 
5 (36%) 
stroke 
survivors; 
9 (74%)  
Health 
professio
nals 
Stroke beliefs, medication issues, patient experience and 
relationships with healthcare professionals 
Chambers, 
2011, UK 
26 (13 low adhering 
and 13 high adhering) 
ischaemic stroke 
survivors living 
independently 
Within 15 
months 
post 
stroke 
Purposive Face-to-face 
interviews  
63.5 (NS) 
stroke 
survivors 
46% 
stroke 
survivors 
Experience of taking medication and beliefs about 
medication  
26 
Chambers, 
2014, UK  
28 stroke and TIA 
stroke survivors living 
in the community 
Three 
months 
to 6.5 
months 
post 
discharge 
Convenience Face-to-face 
interviews 
68.3 (51 to 85) 39%  
stroke 
survivors 
Aspects of the medication which may change as a result 
of a switch to another brand of medication;  stroke 
survivors understanding of generic medication and the 
reasons behind medication switches; the impact 
medication switches had on stroke survivors medication 
taking 
 
Gallacher, 
2018, UK 
29 stroke survivors 
living in the 
community and an 
unspecified number 
of their carers 
2-241 
months, 
mean 
68.3 
months.  
Purposive; 
from both 
hospital OPD 
and GPs 
Face-to-face 
interviews 
Stroke 
survivors -
Mean 68 years 
(range 40-49 
to 80-89, exact 
ages not 
given) 
44.8% Treatment burden after stroke 
Factors affecting capacity to cope with treatment burden 
Jamison, 
2016, UK 
28 stroke survivors, 
14 accompanying 
caregivers, 5 GPs 
 
4 months 
to 18 
years;  
mean 5.7 
years 
Purposive Face-to-face 
interviews 
74.0 (61 to 93) 
stroke 
survivors 
25%  
stroke 
survivors 
Patient 
Health and medication since stroke; medication taking.  
Caregiver 
Role in managing patient’s medication; barriers and 
concerns; strategies to improve medication taking.  
GP  
Treatment for secondary prevention of stroke; strategies 
to improve medication taking; patient understanding and 
management; limitations of current regimens for 
secondary prevention 
Jamison 2017, 
UK 
84 (49 stroke 
survivors; 33 care 
givers; 2 not known) 
37 (44%) 
(0-12 
months); 
25 (30%) 
(1-5 
years); 4 
(5%) (6-
10 years); 
2 (2%)  
Purposive Analysis of 
on-line 
discussion 
posts 
58 (32-91) 
stroke 
survivors 
(45%) 
female; 
7% 
unknown 
The PAPA framework including: (beliefs and preferences) 
and practical (capability and resources) factors which 
have an influence on stroke survivors commencing and 
continuing treatment. Barriers and facilitators of 
adherence to secondary prevention medications 
27 
(11 and 
15 years); 
1 (1%) (15 
years +); 
15 (18%) 
unknown 
Kelly, 2011, 
UK 
11 people with 
dysphagia living 
independently >60 
years (2, 18% stroke 
survivors) 
NS Convenience Face-to-face 
interviews  
NS 0%  Medication formulation; information exchange; factors 
affecting medication adherence; strategies used for 
swallowing medication 
Izuka, 2017, 
UK 
50 (33 stroke 
survivors, 17 care 
givers) 
Mean 2.3 
years 
Purposive Analysis of 
on-line 
discussion 
posts 
49.0 (17–88)  
stroke 
survivors 
54%  
stroke 
survivors 
Participants engaged in free discussion about any topic. 
Nichols, 2017, 
Ghana 
38 (13 stroke 
survivors, 9 
caregivers, 6 faith-
based community 
leaders. Interviews: 
10 healthcare 
providers and 
hospital 
administrators) 
8 less 
than 1 
year and 
5 over 1 
year post 
stroke 
 
Purposive Focus groups 
and face-to-
face 
interviews 
55.3 (NS) 
Overall group  
64% 
Overall 
group 
Focus groups: (1) beliefs about HTN and stroke risk factor 
control, (2) existing self-management strategies and 
experiences, (3) expectations and preferences, (4) 
knowledge and (5) impressions of nurse navigators and 
remote monitoring or mHealth technology. 
Interviews: (1) current approaches to HTN treatment and 
stroke risk factor control, (2) perceived gaps in care, (3) 
cultural competence or communication, (4) knowledge 
of treatment guidelines, (5) impressions of in-hospital 
health education, involvement of nurse navigators and 
home BP monitoring 
Souter, 2014, 
UK 
30 stroke survivors 
with ischaemic or 
haemorrhagic stroke 
from acute stroke, 
rehabilitation or 
outpatient settings 
Within 12 
months of 
stroke 
onset 
Purposive Face-to-face 
interviews 
69 (32–86) 
stroke 
survivors 
50%  
stroke 
survivors 
Questions in relation to condition (stroke); questions in 
relation to medicines; side effects or worries about 
medicines; inconvenience/ effects on lifestyle; 
information provision; support 
28 
 
29 
Table 2: Exemplar first-order quotes from a qualitative synthesis of medication-taking after stroke. 
Theme Exemplar first order quote Participant Study 
Information work 
Positive examples ‘I think that taking the time to explain the 
prescription to outpatients is really 
important’    
HCP Bauler 2012 
‘…she (the stroke nurse) sent me out some 
leaflets on things for HRT, and you know, 
anything I needed to ask her, she was there 
if I needed to phone her … my own GP is 
very good as well.’ 
Patient Chambers 
2011 
‘…the doctors explained to me why they 
wanted me to take it, and they explained 
the best time of day to take it. And I have 
no reason to want to ignore their advice.’ 
Patient Chambers 
2011 
Lack of information 
provision 
 
 
‘There’s a lot of them, I don’t know what 
they’re for. I’ve just always had them.’  
Patient Chambers 
2011 
‘No, I don’t think we’ve got hardly any 
information. We haven’t ever really had a 
lot of information about it have we? You 
just sort of get on with it … I mean perhaps 
I haven’t ever asked enough but … I think 
you should be, told in advance.’   
Carer Jamison 2016 
‘I don’t know why I take them, but it tells 
you on each one, you know, what it’s for … 
I wouldn’t say I know what they’re for.’ 
Patient Jamison 2016 
‘You’d get more information out of a leaflet 
than you do with a person trying to tell 
you.’  
Patient Souter 2014 
Need for ongoing 
information 
‘There's one time it's such and such a brand 
and the next it's another brand, so you get 
used to seeing maybe a particular colour or 
shape and then he changes it and you're, 
'Which one's which now?'  
Patient Chambers 
2014 
‘Well, if the chemist gives you another 
make and the box changes as well... that to 
me would confuse some people and it 
makes you think a little bit harder.’  
Patient Chambers2014 
‘It was a smaller, a different-shaped tablet 
and I thought, 'I wonder if it's the wrong 
thing... I'll go to the chemist,' ... but no, he 
said, 'It's just a different...' em, what would 
you say, manufacturer?’  
Patient Chambers 
2014 
‘What I did notice was that the simvastatin 
changed colour, changed from a pink tablet 
to a white tablet, why that was I don't 
know, but I'm assuming that it's still the 
same stuff that's inside the capsule... I 
suppose I'm doing in that case is trusting 
Patient Chambers 
2014 
30 
the pharmacist is doing their job properly... 
‘  
Healthcare Work 
Negative aspects of 
healthcare work 
‘There is no way I’m going to take 
warfarin… and have to go for blood tests… I 
just hate them... suppose I had to go on a 
Monday… well once it was over I would 
start worrying for the next Monday.’  
Patient Souter 2014 
‘I should go and see the doctor but making 
an appointment is such a kerfuffle.’   
Patient Souter 2014 
I should have really made an appointment 
to go and see her (GP). I haven’t seen her 
since this happened 14 months ago.’  
Patient Chambers 
2011 
‘I have to take 10 a day now altogether but 
I went up there [to the practice] to say can I 
get off some of these tablets, and I come 
back, and I was on an extra one, so I’ve not 
been up since.’   
Patient Jamison 2016 
Patient-centred 
healthcare work 
‘They changed his medication to cheaper 
cholesterol and [he] was physically ill. He 
couldn’t cope on it at all, so he went back, 
and the doctor said, “oh well it was just to 
try” and they put him back on the others.’  
Carer Jamison 2016 
Carer Work 
Organising the 
medication 
‘People with family or with a good social 
support have fewer difficulties in managing 
their treatment.’   
HCP  Bauler 2012 
‘He’s quite organised now. He made quite a 
mess of it in the beginning, but we’ve got 
him organised now. ‘   
Carer  Chambers 
2011 
‘…my sister, she’s got everything well 
organised (for me) on my wee meal table.’  
Patient  Chambers 
2011 
‘My son was away. He always makes sure I 
get my prescriptions and I forgot.’   
Patient Chambers 
2011 
Overseeing 
medication-taking 
‘My wife sorts it out and that’s why I don’t 
know so much about it you see she [taps]. 
She puts them there, I take them and that’s 
it.’ 
Patient Jamison 2016 
‘The warfarin one, my daughter always 
makes sure I take it.’ 
Patient Gallacher 2018 
Conflicts between 
the patient and 
carer 
‘What upsets me is that the doesn't like to 
take medication or doesn't want to get the 
prescriptions filled or he has one excuse 
after another why he shouldn't take the 
medicine.’  
Carer Bakas 2002 
Emotional Work 
Perceived necessity ‘I have no choice; if I don’t take the 
medication, I will have a new stroke…’ 
Patient Bauler 2012 
‘I know I could die if I don’t take my 
medication.’   
Patient  Bauler 2012 
31 
‘They have to understand that they could 
have another stroke.’    
HCP Bauler 2012 
‘No, I mean I just accept the fact that it’s 
got to be done and it’s bad… I’d rather it 
wasn’t, but it’s far better than the 
alternative.’   
Patient Chambers 
2011 
‘I’m sort of, a little bit annoyed that I’ve 
missed them but, no it doesn’t worry me. It 
would worry me if … I missed them for 3 or 
4 days but a day, no.’   
Patient Jamison 2016 
Fear of having 
another stroke 
‘I could have another one and it scares me.’ Patient  Bauler 2012 
‘We don’t talk about it (recurrent stroke 
risk), because they are already so anxious’    
HCP Bauler 2012 
Concerns about 
taking medication 
‘It’s a lot of tablets. At one point I just felt, I 
felt as if I was dizzy with all these tablets.’ 
Patient  Chambers 
2011 
‘I told myself that things will no longer be 
normal.’   
Patient  Bauler 2012 
‘On a Sunday I don’t take the water one 
(diuretic) … everybody looks at you if 
you’ve got to waltz to the back of the 
church to go to the loo.’ 
Patient  Souter 2014 
‘Among the men you notice that they stop 
taking their medications due to the fear of 
getting sexual dysfunction…’ 
not stated Nichols 2017 
Practical Work 
Logistical and 
technical work 
‘I only remember to take the others … if I 
take them out of the cupboard the night 
before and leave them on the top. If I 
didn’t take them out, I would probably 
forget … because it isn’t the first thing that 
I think of … when I first get up.’  
Patient  Jamison 2016 
Physical sequelae of 
stroke 
‘I have a problem swallowing... these are 
quite big ones, these clopidogrel I bite into 
them, I just resorted to... I bite into them 
then I take the water or coffee, I manage to 
swallow the bits...’      
Patient  Chambers 
2014 
‘From a patient’s perspective it’s usually it’s 
just physically a lot of tablets you have to 
swallow.’  
HCP Jamison 2016 
‘Some of the, the pills are a hell of a 
trouble, you know the bubble wrap, 
flipping them out especially with my hands 
not as strong as they should be.’ 
Patient  Jamison 2016 
Evolving and 
maintaining a 
medication routine 
‘I just do it routinely now. It’s just part of 
when you get up in the morning, what you 
go through, you know. Have a shower, 
brush your teeth…’ 
Patient  Chambers 
2011  
 
‘…I forgot to take the pills with me (on a 
weekend away) but I went down to the 
chemist, and bought aspirins, but they are 
Patient  Chambers 
2011 
32 
small aspirins, so I just halved the big 
aspirins…’ 
Modifying the 
routine 
‘If I go out in the evening, I make sure I’ve 
got my pills in my pill box, ready to be 
taken.’   
Patient Chambers 
2011 
‘For example, the aspirin is (now) the same 
colour as the lisinopril, and the lisinopril's 
just a slightly bigger tablet. So, I've got to 
dissolve the aspirin but keep the lisinopril 
whole, so that's kind of... more an 
inconvenience than anything else, you 
know?’  
Patient Chambers 
2014 
‘There used to be paper at the back [of the 
packet] and now I am sure some of them 
are plasticky, and I’m sitting with a knife 
trying to cut them [tablets] out. ‘  
Patient Souter 2014 
‘Well they’ve just changed one of them, it’s 
the same stuff only… it’s got no days on, 
most of them have Monday, Tuesday, 
Wednesday so if I go today and I see 
Monday’s there, I know I’ve forgotten one 
…they've changed one of them and it’s got 
no bloody days on it at all.’  
Patient Gallacher 2018 
Affordability ‘Now it's like all these other pills and the 
insulin and the blood sugar monitor.  We 
have to constantly keep buying all this 
stuff.’      
Carer Bakas 2002 
‘Some of the drugs are costly and it is not 
easy to buy all of them.’ 
Not stated Nichols 2017 
‘Well, they just say (no), 'Well, it comes out 
of our budget.'   
Patient Chambers 
2014 
Trust 
Imperceptible 
benefit 
‘They do not feel sick, so they think that if 
they do not take their medications they will 
not be sick.’   
HCP Bauler 2012 
‘Patients are tempted to stop taking their 
medications as they no longer exhibit 
clinical symptoms.’    
HCP Bauler 2012 
‘I didn’t think at first when I was taking 
them that they were doing me any good. 
And I did stop taking them.’   
Patient Chambers 
2011 
‘I’ve been taking all that for four years, I 
might not need it.’ 
Patient Gallacher 2018 
Trust in the efficacy 
of specific 
medication 
‘I think aspirins are good for you. That’s the 
only one I fancy. Well it thins the blood and 
I think, well by thinning the blood it flows 
better and that stops any clots, so I do like 
to take it. I just don’t see why I’m taking 
other medication, I’m not fat or anything 
like that.  I don’t get very high blood 
Patient Jamison 2016 
33 
pressure, and well cholesterol, what is 
cholesterol?’ 
‘Well, if it was simvastatin I think that 
would matter. The other ones I think you 
could miss out a few without affecting my 
blood pressure.’  
Patient Chambers 
2011 
‘Since taking all these medicines my blood 
pressure has been coming down.’  
Patient Souter 2014 
Beliefs about 
healthcare 
‘We have this belief that medicines do not 
help.’  
Not stated Nichols 2017 
‘I feel that whatever the doctor prescribes, 
they know what they are doing, and talking 
about… I’ve got trust in the doctor.’ 
Patient Chambers 
2011 
‘So, if the doctor says take ten pills a day, 
I’ll, I’ll do it … he makes the decision and 
erm he, he’s the boss man as you might 
say, who knows what he’s up to.’   
Patient Jamison 2016 
‘He’s the pharmacist and he deals with 
drugs. He’s bound to know what’s what. He 
didn’t pass his qualifications just to pop out 
some pills and say there you are.’  
Patient  Souter 2014 
 
 
                                                                                                                                                                                                                                              
 
